Stockscreener 앱 받기
17.17
0.40%
-0.12
전일 마감가:
$17.29
열려 있는:
$17.29
하루 거래량:
72,870
Relative Volume:
0.42
시가총액:
$896.71M
수익:
-
순이익/손실:
$-41.43M
주가수익비율:
-21.73
EPS:
-0.79
순현금흐름:
$-39.97M
1주 성능:
+7.30%
1개월 성능:
+43.63%
6개월 성능:
+93.93%
1년 성능:
+45.82%
1일 변동 폭
$17.05
$17.48
1주일 범위
$15.25
$17.48
52주 변동 폭
$6.00
$20.50
Gh Research Plc Stock (GHRS) Company Profile
GHRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
17.23 | 960.22M | 0 | -41.43M | -39.97M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.88 | 123.00B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.50 | 59.66B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.84 | 41.84B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
569.14 | 33.98B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
289.00 | 27.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-03-13 | 개시 | Guggenheim | Buy |
| 2025-03-07 | 개시 | RBC Capital Mkts | Outperform |
| 2025-02-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-08-16 | 개시 | H.C. Wainwright | Buy |
| 2022-06-16 | 개시 | ROTH Capital | Buy |
모두보기
Gh Research Plc 주식(GHRS)의 최신 뉴스
FY2025 EPS Estimates for GH Research Lifted by HC Wainwright - Defense World
Wall Street Analysts Believe GH Research (GHRS) Could Rally 107.25%: Here's is How to Trade - Yahoo Finance
(GHRS) Long Term Investment Analysis - news.stocktradersdaily.com
What makes GH Research PLC stock price move sharplyFree Market Dynamics Reports - Newser
Why GH Research PLC stock attracts strong analyst attentionFree Stock Market Beginners Guide - Newser
How GH Research PLC stock performs during market volatilityFree Wealth-Building Investment Strategies - Newser
GH Research stock awaits FDA response on clinical hold, says Canaccord - Investing.com
Long Term Trading Analysis for (GHRS) - news.stocktradersdaily.com
JMP reiterates GH Research stock rating on competitor’s positive results By Investing.com - Investing.com Canada
Health Care Stocks Stumble Amid Market Adjustments - Finimize
GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule - The Manila Times
GH Research Submits IND Hold Response to FDA - TipRanks
GH Research announces annual general meeting for July 31 - Investing.com
GH Research Announces AGM and Key Resolutions for July 2025 - TipRanks
J Sainsbury plc (OTCMKTS:JSAIY) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Millennium Management LLC Acquires Shares of 20,761 GH Research PLC (NASDAQ:GHRS) - Defense World
GH Research to Participate in Neuro Perspectives Conference - TipRanks
Two Sigma Investments LP Makes New Investment in GH Research PLC (NASDAQ:GHRS) - Defense World
Cantor Fitzgerald Weighs in on GH Research FY2026 Earnings - Defense World
Cantor Fitzgerald Initiates Coverage of GH Research (GHRS) With Overweight Rating - Insider Monkey
GH Research (NASDAQ:GHRS) Now Covered by Cantor Fitzgerald - Defense World
GHRS Stock Coverage Initiated with Positive Outlook | GHRS Stock News - GuruFocus
cantor fitzgerald maintains overweight rating on gh research stock By Investing.com - Investing.com Canada
cantor fitzgerald maintains overweight rating on gh research stock - Investing.com Australia
BNP Paribas Financial Markets Takes $44,000 Position in GH Research PLC (NASDAQ:GHRS) - Defense World
How To Trade (GHRS) - news.stocktradersdaily.com
Northern Trust Corp Has $286,000 Holdings in GH Research PLC (NASDAQ:GHRS) - Defense World
GH Research to Present at ASCP Meeting on Breakthrough Depression Treatment - TipRanks
GH Research to Present at ASCP Meeting on Depression Treatments - TipRanks
GH Research PLC (NASDAQ:GHRS) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Beckley’s psychedelic reduces depression - BioWorld MedTech
GH Research (NASDAQ:GHRS) Upgraded at Cantor Fitzgerald - Defense World
GH Research (GHRS) Highlights Phase 2b Results at Clinical Confe - GuruFocus
GH Research (GHRS) Highlights Phase 2b Results at Clinical Conference | GHRS Stock News - GuruFocus
GH Research Showcases Promising Depression Treatment Data at ASCP Meeting - TipRanks
GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting - Yahoo
GH Research’s (GHRS) “Buy” Rating Reiterated at HC Wainwright - Defense World
Guggenheim Cuts GH Research (NASDAQ:GHRS) Price Target to $29.00 - Defense World
GH Research (GHRS) Price Target Lowered by Guggenheim | GHRS Sto - GuruFocus
GHRS Stock: HC Wainwright & Co. Reiterates Buy Rating | GHRS Sto - GuruFocus
GH Research: Promising Clinical Results and Strong Financial Position Justify Buy Rating - TipRanks
GH Research (GHRS) Price Target Lowered by Guggenheim | GHRS Stock News - GuruFocus
Psychedelic: Compass, GH Research, MindMed report quarterly earnings - Yahoo Finance
GH Research PLC Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
GHRS Reports Strong Financial Position with Increased Cash Holdi - GuruFocus
GH Research Reports Q1 2025 Financial Results Amidst Ongoing Challenges - TipRanks
GH Research PLC Reports Positive Phase 2b Trial Results for GH001 in Treatment-Resistant Depression and Financial Update for Q1 2025 - Nasdaq
GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates - Stock Titan
What Makes GH Research (GHRS) a New Buy Stock - Yahoo Finance
Where are the Opportunities in (GHRS) - news.stocktradersdaily.com
Gh Research Plc (GHRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.69%
2.49%
자본화:
|
볼륨(24시간):